The CAR T-cell Therapy market size accounted for USD 2.28 billion in 2022 and is estimated to achieve a market size of USD 6.7 billion by 2032, growing at a CAGR of 11.39% from 2023 to 2032.
Chimeric antigen receptors (CAR) are genetically engineered protein constructs that can be incorporated into a patient’s own cytotoxic T cells to help them to recognize and fight cancer cells. CAR T-cell therapy is used in the treatment of acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others
Increase in incidence of cancer and strong product pipeline are projected to drive the global CAR T-cell therapy market
Increase in incidence of cancer is likely to boost the growth of the global CAR T-cell therapy market during the forecast period. Cancer is a leading cause of death across the world. Majority of cancer cases are caused due to lifestyle-related factors such as alcohol consumption, tobacco consumption, and some food-related factors such as nitrites and polyaromatic hydrocarbons. According to World Health Organization statistics, in 2020, an estimated 19.3 million new cases of cancer and 10.0 million deaths were reported across the globe.
Major market players focus on research & development to develop new CAR T-cell therapy products for treatment of different types of cancer. This is another major factor fueling the growth of the global CAR T-cell therapy market. Majority of CAR T clinical researches focus on hematological cancer (57%), followed by CNS (8%), GI (6%), skin (5%), genitourinary (4%), breast (4%), gynecologic (4%), respiratory (3%), sarcoma (2%), mesothelioma (2%), and others (5%).
Report Scope of the CAR T-cell Therapy Market
Report Coverage |
Details |
Market Size in 2023 |
USD 2.54 Billion |
Market Size by 2032 |
USD 6.7 Billion |
Growth Rate from 2023 to 2032 |
CAGR of 11.39% |
Base Year |
2022 |
Forecast Period |
2023 to 2032 |
Segments Covered |
Product Type, Indication, End-user |
Regions Covered |
North America, Europe, Asia Pacific, Middle East & Africa, Latin America |
Continuity in Provision of Medical Products Gains Importance During COVID-19 Outbreak
The coronavirus outbreak has generated a significant repercussion on the administration of adoptive cell therapies, including chimeric antigen receptor (CAR) T-cells. Decline in people transit, closing of borders, and confinement of the population has impacted the supply chains of these life-saving medical products. This is anticipated to slowdown the growth of the CAR T-cell therapy market during the ongoing pandemic.
Although hospitals have been compelled to change their usual workflows to cope with the saturation of health services by hospitalized patients, stakeholders in the CAR T-cell therapy market are increasing efforts to ensure continuity in offering the treatment. This is prominent in the case of patients with relapsed/refractory hematologic malignancies. Moreover, the burgeoning growth of telehealth services is encouraging early intervention to attenuate neurotoxicity or cytokine release syndrome with tocilizumab and prophylactic/preventive strategies to prevent infection.
Stakeholders Employ Innovative CAR Engineering Strategies to Improve Treatment Efficacy
The CAR T-cell therapy market is expected to clock a CAGR of 11.39% during the assessment period. The CAR T-cell therapy is known as a revolutionary treatment option for cancer, owing to its remarkably effective and durable clinical responses. However, market stakeholders need to address major limitations to the CAR T-cell therapy, which involves life-threatening CAR T-cell associated toxicities, limited persistence, and issues such as low efficacy against solid tumors. Hence, stakeholders are increasing their research capabilities to combine the CAR T-cell therapy with other anticancer therapies.
Stakeholders in the CAR T-cell therapy market are anticipated to collaborate with researchers, scientists, and biotechnologists to employ innovative CAR engineering strategies in order to improve anti-tumor efficacy, expand clinical efficacy, and limit toxicities. Stakeholders are increasing efforts to improve clinical efficacy in both hematological malignancy and solid tumors to overcome treatment limitations.
In Vivo Gene Delivery to Immune Cells Shows Potential to Improve Medical Outcomes
Several hundred clinical trials of CAR-T have been registered and actively recruiting patients with various malignant & non-malignant conditions are showing rapid pace of innovation in this field. However, substantial challenges currently limit its widespread adoption. The CAR T-cell therapy is potentially expensive with both tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel) in the U.S. when used for high-grade B-cell lymphomas. Hence, stakeholders in the CAR T-cell therapy market are increasing efforts to reduce cost in order to meet the expanding indications of CAR-T.
Publically funded healthcare systems where resource allocation is strained, healthcare providers are striving to reduce treatment cost for CAR-T. Companies in the CAR T-cell therapy market are gaining awareness about novel strategies such as in vivo gene delivery to immune cells using nanoparticles to improve medical outcomes.
Stringent Regulations for Manufacturing CAR T-Cells Ensure Patient Safety
The CAR T-cell Therapy market size accounted for USD 2.28 billion in 2022 and is estimated to achieve a market size of USD 6.7 billion by 2032. From regulatory point of view, CAR T-cells are an advanced therapy medicinal product (ATMP) in the European Union (EU). Companies are increasing the availability of tissue-engineered products, gene therapy medicinal products, and somatic cell therapy medicinal products, among others. Such products are playing a crucial role in the treatment of cancer and hereditary diseases as well as in regenerative medicine.
CAR T-cells as an ATMP can be generated by either viral transduction, leading to a permanent CAR expression or by using mRNA. Companies in the CAR T-cell therapy market are increasing R&D investments in this field of the study. Manufacturing, approvals, and regulations of these therapies are potentially complex to protect patients.
Immunotherapy Helps in Treatment of New and Difficult Cancer Indications
The immunotherapy industry is an ever-evolving landscape with interest in CAR T-cells, checkpoint inhibitors, and bispecific antibodies exploding in the recent years. Likewise, Ceylad Oncology - a clinical stage biotechnology company, is gaining recognition for increasing its focus on CAR T-cell therapies, which involve engineering patient or donor T cells to display a CAR that targets the immune cells to cancer cells via antigen receptor binding. Such innovations are helping healthcare providers to treat new and difficult cancer indications, including solid tumors, and harness the immune system in a novel way to target new pathways.
Companies in the CAR T-cell therapy market are mainly focusing on immunotherapies that are showing potential in standalone treatments and in administration in combination with other types of treatments.
BIRAC Acquires Recognition for Increasing Availability of CAR T-cell Therapy in India
The CAR T-cell therapy is emerging as a breakthrough innovation in cancer treatment. Clinical trials conducted globally are showing promising results in end stage patients and especially, for patients suffering from Acute Lymphocytic Leukemia. Such findings are translating into revenue opportunities for companies in the CAR T-cell therapy market. However, there is a need to increase the availability of CAR T-cell therapy in India. A possible way to increase its availability in India is by reducing the cost of the treatment.
The manufacturing complexity is a major reason for high therapy cost in India. In order to promote and support the development of CAR T-cell technology against cancer and other diseases, the Biotechnology Industry Research Assistance Council (BIRAC) is taking the initiative to invite proposals in India.
Health and Research Policy Frameworks Promote Innovations in Treatment Options
Since medicine continues to be revolutionized by advancements in treatments, CAR T-cell therapies are achieving increased commercialization. Such trends are contributing to the growth of the global CAR T-cell therapy market. For instance, Anixa Biosciences, Inc. is being known for its therapeutics profile in a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T.
CAR T-cell therapies are subject to health and research policy frameworks as well as legal regulations that have a direct influence on international competitiveness. Companies in the CAR T-cell therapy market are adhering to this design framework, which is an important instrument to support research in the EU and to promote innovations. It has been found that there are strict regulations in Germany for the import of medicinal products in order to ensure patient safety.
Some of the prominent players in the CAR T-cell Therapy Market include:
Segments Covered in the Report
This report forecasts the volume and revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor has segmented the CAR T-cell Therapy market.
By Product Type
By Indication
by End-user
By Regions
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Global CAR T-cell Therapy Market Forecast
4.4. Global CAR T-cell Therapy Market Outlook
5. Market Outlook
5.1. Key Industry Events
5.2. Diseases Epidemiology
5.3. Product Pipeline Analysis
5.4. Impact of COVID-19 Pandemic
6. Global CAR T-cell Therapy Market Analysis, by Product Type
6.1. Introduction
6.2. Global CAR T-cell Therapy Market Value Share Analysis, by Product Type
6.3. Global CAR T-cell Therapy Market Forecast, by Product Type
6.3.1. Axicabtagene Ciloleucel
6.3.2. Tisagenlecleucel
6.3.3. Brexucabtagene Autoleucel
6.3.4. Lisocabtagene Maraleucel
6.3.5. Idecabtagene Vicleucel
6.3.6. Others
6.4. Global CAR T-cell Therapy Market Analysis, by Product Type
6.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by Product Type
7. Global CAR T-cell Therapy Market Analysis, by Indications
7.1. Introduction
7.2. Global CAR T-cell Therapy Market Value Share Analysis, by Indication
7.3. Global CAR T-cell Therapy Market Forecast, by Indication
7.3.1. Acute Lymphocytic Leukemia
7.3.2. Diffuse Large B-Cell Lymphoma
7.3.3. Follicular Lymphoma
7.3.4. Mantle Cell Lymphoma
7.3.5. Multiple Myeloma
7.3.6. Others
7.4. Global CAR T-cell Therapy Market Analysis, by Indication
7.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by Indication
8. Global CAR T-cell Therapy Market Analysis, by End-user
8.1. Introduction
8.2. Global CAR T-cell Therapy Market Value Share Analysis, by End-user
8.3. Global CAR T-cell Therapy Market Forecast, by End-user
8.3.1. Hospitals
8.3.2. Cancer Treatment Centers
8.4. Global CAR T-cell Therapy Market Analysis, by End-user
8.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by End-user
9. Global CAR T-cell Therapy Market Analysis, by Region
9.1. Global CAR T-cell Therapy Market Analysis, by Region
9.2. Global CAR T-cell Therapy Market Value Share Analysis, by Region
9.3. Global CAR T-cell Therapy Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
10. North America CAR T-cell Therapy Market Analysis
10.1. North America CAR T-cell Therapy Market Overview
10.2. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country
10.3. North America CAR T-cell Therapy Market Forecast, by Country
10.3.1. U.S.
10.3.2. Canada
10.4. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
10.5. North America CAR T-cell Therapy Market Forecast, by Product Type
10.5.1. Axicabtagene Ciloleucel
10.5.2. Tisagenlecleucel
10.5.3. Brexucabtagene Autoleucel
10.5.4. Lisocabtagene Maraleucel
10.5.5. Idecabtagene Vicleucel
10.5.6. Others
10.6. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indications
10.7. North America CAR T-cell Therapy Market Forecast, by Indication
10.7.1. Acute Lymphocytic Leukemia
10.7.2. Diffuse Large B-Cell Lymphoma
10.7.3. Follicular Lymphoma
10.7.4. Mantle Cell Lymphoma
10.7.5. Multiple Myeloma
10.7.6. Others
10.8. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
10.9. North America CAR T-cell Therapy Market Forecast, by End-user
10.9.1. Hospitals
10.9.2. Cancer Treatment Centers
11. Europe CAR T-cell Therapy Market Analysis
11.1. Europe CAR T-cell Therapy Market Overview
11.2. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Europe CAR T-cell Therapy Market Forecast, by Country/Sub-region
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
11.5. Europe CAR T-cell Therapy Market Forecast, by Product Type
11.5.1. Axicabtagene Ciloleucel
11.5.2. Tisagenlecleucel
11.5.3. Brexucabtagene Autoleucel
11.5.4. Lisocabtagene Maraleucel
11.5.5. Idecabtagene Vicleucel
11.5.6. Others
11.6. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
11.7. Europe CAR T-cell Therapy Market Forecast, by Indication
11.7.1. Acute Lymphocytic Leukemia
11.7.2. Diffuse Large B-Cell Lymphoma
11.7.3. Follicular Lymphoma
11.7.4. Mantle Cell Lymphoma
11.7.5. Multiple Myeloma
11.7.6. Others
11.8. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
11.9. Europe CAR T-cell Therapy Market Forecast, by End-user
11.9.1. Hospitals
11.9.2. Cancer Treatment Centers
12. Asia Pacific CAR T-cell Therapy Market Analysis
12.1. Asia Pacific CAR T-cell Therapy Market Overview
12.2. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Asia Pacific CAR T-cell Therapy Market Forecast, by Country/Sub-region
12.3.1. China
12.3.2. Japan
12.3.3. India
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
12.5. Asia Pacific CAR T-cell Therapy Market Forecast, by Product Type
12.5.1. Axicabtagene Ciloleucel
12.5.2. Tisagenlecleucel
12.5.3. Brexucabtagene Autoleucel
12.5.4. Lisocabtagene Maraleucel
12.5.5. Idecabtagene Vicleucel
12.5.6. Others
12.6. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
12.7. Asia Pacific CAR T-cell Therapy Market Forecast, by Indication
12.7.1. Acute Lymphocytic Leukemia
12.7.2. Diffuse Large B-Cell Lymphoma
12.7.3. Follicular Lymphoma
12.7.4. Mantle Cell Lymphoma
12.7.5. Multiple Myeloma
12.7.6. Others
12.8. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
12.9. Asia Pacific CAR T-cell Therapy Market Forecast, by End-user
12.9.1. Hospitals
12.9.2. Cancer Treatment Centers
13. Latin America CAR T-cell Therapy Market Analysis
13.1. Latin America CAR T-cell Therapy Market Overview
13.2. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Latin America CAR T-cell Therapy Market Forecast, by Country/Sub-region
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
13.5. Latin America CAR T-cell Therapy Market Forecast, by Product Type
13.5.1. Axicabtagene Ciloleucel
13.5.2. Tisagenlecleucel
13.5.3. Brexucabtagene Autoleucel
13.5.4. Lisocabtagene Maraleucel
13.5.5. Idecabtagene Vicleucel
13.5.6. Others
13.6. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
13.7. Latin America CAR T-cell Therapy Market Forecast, by Indication
13.7.1. Acute Lymphocytic Leukemia
13.7.2. Diffuse Large B-Cell Lymphoma
13.7.3. Follicular Lymphoma
13.7.4. Mantle Cell Lymphoma
13.7.5. Multiple Myeloma
13.7.6. Others
13.8. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
13.9. Latin America CAR T-cell Therapy Market Forecast, by End-user
13.9.1. Hospitals
13.9.2. Cancer Treatment Centers
14. Middle East & Africa CAR T-cell Therapy Market Analysis
14.1. Middle East & Africa CAR T-cell Therapy Market Overview
14.2. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.3. Middle East & Africa CAR T-cell Therapy Market Forecast, by Country/Sub-region
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East & Africa
14.4. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
14.5. Middle East & Africa CAR T-cell Therapy Market Forecast, by Product Type
14.5.1. Axicabtagene Ciloleucel
14.5.2. Tisagenlecleucel
14.5.3. Brexucabtagene Autoleucel
14.5.4. Lisocabtagene Maraleucel
14.5.5. Idecabtagene Vicleucel
14.5.6. Others
14.6. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
14.7. Middle East & Africa CAR T-cell Therapy Market Forecast, by Indication
14.7.1. Acute Lymphocytic Leukemia
14.7.2. Diffuse Large B-Cell Lymphoma
14.7.3. Follicular Lymphoma
14.7.4. Mantle Cell Lymphoma
14.7.5. Multiple Myeloma
14.7.6. Others
14.8. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
14.9. Middle East & Africa CAR T-cell Therapy Market Forecast, by End-user
14.9.1. Hospitals
14.9.2. Cancer Treatment Centers
15. Competition Landscape
15.1. Competition Matrix
15.2. Company Profiles
15.2.1. Pfizer Inc.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. Financial Overview
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. Novartis AG
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. Financial Overview
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Bristol-Myers Squibb
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. Financial Overview
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. Amgen, Inc.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. Financial Overview
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. Sorrento Therapeutics, Inc.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. Financial Overview
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Johnson & Johnson Services, Inc.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. Financial Overview
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. Gilead Sciences, Inc.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. Financial Overview
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. Merck & Co., Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. Financial Overview
15.2.8.4. SWOT Analysis
15.2.8.5. Strategic Overview
15.2.9. bluebird bio, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. Financial Overview
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview